Chase Investment Counsel Corp Sells 5,153 Shares of Gilead Sciences, Inc. $GILD

Chase Investment Counsel Corp lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,141 shares of the biopharmaceutical company’s stock after selling 5,153 shares during the quarter. Chase Investment Counsel Corp’s holdings in Gilead Sciences were worth $570,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Howard Hughes Medical Institute acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $30,000. Finally, MTM Investment Management LLC grew its holdings in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a deal valued at about $7.8B (cash $115/share + $5 CVR), giving Gilead full control of Anito‑cel, a next‑generation CAR‑T for multiple myeloma that could reach regulators this year — a clear strategic boost to Gilead’s oncology franchise. Gilead Sciences to Acquire Arcellx
• Positive Sentiment: Sell‑side support: Needham reaffirmed a “buy” on GILD with a $170 price target, highlighting upside based on pipeline and M&A execution, which provides analyst backing for the medium‑term thesis. Analyst Reaffirmation (Benzinga)
• Neutral Sentiment: Gilead scheduled several investor‑conference presentations (TD Cowen, Leerink, Barclays) in early March — useful for management to frame the Arcellx rationale and provide pipeline / guidance color. Gilead to Present at Upcoming Investor Conferences
• Neutral Sentiment: Health‑care sector dynamics and a mixed broader market (including a late‑day drop in the Dow) are a moderating force — sector strength earlier in the session partly offset by broader risk‑off moves. Sector Update (Yahoo Finance)
• Negative Sentiment: A law firm (Kahn Swick & Foti) is investigating the Arcellx sale for adequacy of price and process, which raises the risk of litigation or a proxy fight that could complicate closing or create management distraction. Arcellx Investor Alert (BusinessWire)
• Negative Sentiment: Market concern about the premium and $7.8B price tag (deal cited as ~68–80% premium) is weighing on Gilead — investors are parsing near‑term cash/valuation impact, integration risk and whether the price fairly reflects risk for an outpatient oncology program. Deal Coverage (Reuters)

Analyst Ratings Changes

Several analysts have issued reports on GILD shares. Wells Fargo & Company upped their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. TD Cowen boosted their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Argus raised their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Daiwa Securities Group upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $155.44.

Gilead Sciences Trading Down 1.0%

Shares of Gilead Sciences stock opened at $149.83 on Tuesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The firm has a 50-day moving average of $134.07 and a 200-day moving average of $124.08. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The stock has a market cap of $185.89 billion, a PE ratio of 22.13, a PEG ratio of 2.01 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.68%.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,891 shares of company stock worth $45,091,556 in the last quarter. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.